Furthermore, Kim et al. identified CXCR4 as a cause of primary resistance to idelalisib, a potent therapeutic agent that selective inhibits PI3Kδ in ABC DLBCL [143]. The gene discussed is CXCR4; the disease is diffuse large B-cell lymphoma.